dc.contributor.author
Witkowski, Marco
dc.contributor.author
Witkowski, Mario
dc.contributor.author
Saffarzadeh, Mona
dc.contributor.author
Friebel, Julian
dc.contributor.author
Tabaraie, Termeh
dc.contributor.author
Ta Bao, Loc
dc.contributor.author
Chakraborty, Aritra
dc.contributor.author
Dörner, Andrea
dc.contributor.author
Stratmann, Bernd
dc.contributor.author
Tschoepe, Diethelm
dc.contributor.author
Winter, Samantha J.
dc.contributor.author
Krueger, Andreas
dc.contributor.author
Ruf, Wolfram
dc.contributor.author
Landmesser, Ulf
dc.contributor.author
Rauch, Ursula
dc.date.accessioned
2020-04-06T08:43:12Z
dc.date.available
2020-04-06T08:43:12Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/27064
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-26825
dc.description.abstract
BACKGROUND:
Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blood-borne TF promotes factor (F) Xa generation resulting in a pro-thrombotic state and cardiovascular complications. MicroRNA (miR)s impact gene expression on the post-transcriptional level and contribute to vascular homeostasis. Their distinct role in the control of the diabetes-related procoagulant state remains poorly understood.
METHODS:
In a cohort of patients with poorly controlled type 2 diabetes (n = 46) plasma levels of miR-181b were correlated with TF pathway activity and markers for vascular inflammation. In vitro, human microvascular endothelial cells (HMEC)-1 and human monocytes (THP-1) were transfected with miR-181b or anti-miR-181b and exposed to tumor necrosis factor (TNF) α or lipopolysaccharides (LPS). Expression of TF isoforms, vascular adhesion molecule (VCAM) 1 and nuclear factor (NF) κB nuclear translocation was assessed. Moreover, aortas, spleen, plasma, and bone marrow-derived macrophage (BMDM)s of mice carrying a deletion of the first miR-181b locus were analyzed with respect to TF expression and activity.
RESULTS:
In patients with type 2 diabetes, plasma miR-181b negatively correlated with the procoagulant state as evidenced by TF protein, TF activity, D-dimer levels as well as markers for vascular inflammation. In HMEC-1, miR-181b abrogated TNFα-induced expression of flTF, asTF, and VCAM1. These results were validated using the anti-miR-181b. Mechanistically, we confirmed a miR-181b-mediated inhibition of importin-α3 (KPNA4) leading to reduced nuclear translocation of the TF transcription factor NFκB. In THP-1, miR-181b reduced both TF isoforms and FXa generation in response to LPS due to targeting phosphatase and tensin homolog (PTEN), a principal inducer for TF in monocytes. Moreover, in miR-181-/- animals, we found that reduced levels of miR-181b were accompanied by increased TF, VCAM1, and KPNA4 expression in aortic tissue as well as increased TF and PTEN expression in spleen. Finally, BMDMs of miR-181-/- mice showed increased TF expression and FXa generation upon stimulation with LPS.
CONCLUSIONS:
miR-181b epigenetically controls the procoagulant state in diabetes. Reduced miR-181b levels contribute to increased thrombogenicity and may help to identify individuals at particular risk for thrombosis.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Diabetes complications
en
dc.subject
Diabetes mellitus
en
dc.subject
Endothelial cells
en
dc.subject
Tissue factor
en
dc.subject
Vascular homeostasis
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Vascular miR‐181b controls tissue factor‐dependent thrombogenicity and inflammation in type 2 diabetes
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
20
dcterms.bibliographicCitation.doi
10.1186/s12933-020-0993-z
dcterms.bibliographicCitation.journaltitle
Cardiovascular Diabetology
dcterms.bibliographicCitation.originalpublishername
BMC
dcterms.bibliographicCitation.volume
19
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
32066445
dcterms.isPartOf.eissn
1475-2840